                 |
| Aspen Cancer Conference Archives
See Also: History and Milestones With more than 20 years of conferences and accompanying abstracts, we have amassed an extraordinary amount of information relating to our cancer research programs and other studies. To view a brief summary of a previous year's conference, simply click on the
The TWENTY-SECOND ASPEN CANCER CONFERENCE (July15-18, 2007): Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy included sessions on the following:
As has become the norm, beneficial and sometimes lively discussions followed the presentations. A special public session was held at The Given Institute. The session included a silent auction, a reception and lectures on Colon Cancer Prevention, Diagnosis and Therapy. Lectures were provided by well known scientists and clinicians Raymond N. DuBois, M.D., Ph.D., Bob Pinedo, M.D., and David R. Parkinson, M.D.; a panel discussion followed. A satellite meeting, “Frontiers in Clinical Oncology” (July 19-20, 2007) addressed the following: Cancer Therapy and Cancer Biomarkers. Selected Aspen Cancer Conference Fellows presented poster abstracts at a special evening session that included presentation of the Second Theodore T. Puck Award to Mona L. Gauthier, Ph.D., who was nominated by Thea D. Tlsty, Ph.D. of the University of California, San Francisco. The TWENTY-FIRST ASPEN CANCER CONFERENCE (July 16-19, 2006): Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy featured an excellent program that explored the following: Micro RNAs and Cancer, Predictive Oncology/Toxicology, Oncogenic Targets of Mitosis, Revisiting Formaldehyde, Micro Environment in Cancer, Hormonal and Environmental Carcinogenesis, Tumor Stem Cells, Prostate Cancer, Drug Resistance, Drug Side Effects, Angiogenesis and Hypoxia, and New Molecular Targets. Building on the success of a public event at the 2005 Twentieth Aspen Cancer Conference, a public event was again held at the Paepcke Auditorium. This special event included a silent auction, a reception, a performance by Lutenist Daniel Swenberg, and lectures by two internationally recognized scientists, J. Michael Bishop, M.D. and Raymond N. DuBois, M.D., Ph.D. A panel discussion followed that included the featured speakers plus Cecil B. Pickett, Ph.D., President of Schering-Plough Research Institute, Ira S. Jaffrey, M.D., a local oncologist and Sandy Jaffrey, a breast cancer survivor. As in past years, Aspen Cancer Conference Fellows presented poster abstracts at an evening session. Another special evening session featured Thomas A. Waldmann, M.D., of the National Cancer Institute who presented a keynote address, “Tumor Immunology: Past, Present and Future”. Also noteworthy, a satellite meeting of the Aspen Cancer Conference followed the regular conference. Titled “Cancer Prevention: Life Style or Nutrition?” the meeting began with a special lecture on the evening of July 19 and continued July 20 and 21, 2006. Subjects addressed included: Calorie Restriction, Natural Products and Cancer Prevention, and Natural Products: Mechanistic Approaches for Cancer Prevention. The TWENTIETH ASPEN CANCER CONFERENCE (July 24-28, 2005) celebrated twenty years of conference excellence by once again featuring an assembly of outstanding scientific leaders from throughout the world. The Conference had as its premier event a special session that featured Harold Varmus, M.D., President of Memorial Sloan-Kettering Cancer Center. Another notable speaker was Terry Dornbush, two time cancer survivor and former Ambassador to The Netherlands who shared with the audience what he called the “best and the worst of times for Terry Dornbush”; this was a truly inspirational talk. Karen Allred, an accomplished pianist from North Carolina charmed the audience with “Variations on a Theme of Corelli” by Sergei Rachmaninoff. The five day Conference featured a return of previous keynote speakers. Another special feature was an entire day devoted to Progress in Drug Development with talks on the regulatory perspective, animal models, patient stratification, new drugs in various stages of development as well as other related subjects. An evening event provided an update on cancer therapy and research advances; featured speakers were Cecil Pickett, Ph.D., President of Schering-Plough Research Institute, as Chair and J. Carl Barrett, Ph.D., of Novartis Institutes for Biomedical Research, and James H. Doroshow, M.D., of the National Cancer Institute. Additional subjects addressed at this five day Conference included the following: metastasis; inflammation and cancer; risk assessment; technology innovations; stress and cancer; and apoptosis. Fifteen Aspen Cancer Conference Fellows presented poster abstracts at an evening session. The TWENTIETH ASPEN CANCER CONFERENCE truly celebrated twenty years of excellence from the laboratory to the clinic.
The NINETEENTH ASPEN CANCER CONFERENCE (July 25-27, 2004) addressed the following: Metastasis; Gene Environment Interactions; Inflammation; Personalized Medicine; Signaling Networks in Tumorigenesis; Risk Assessment; Ubiquitin and Proteasomes; Stem Cells; Cancer Therapy; and DNA Repair. Discussions were as enthusiastic as ever as representatives from academia, industry, and government exchanged research findings and goals as they continue their quest for a cancer free world. In addition, Sir David P. Lane, Ph.D., the University of Dundee, Dundee, Scotland, presented a special lecture, “2004 – p53 – 25 Years” which was well received by all. As in past years, selected Aspen Cancer Conference Fellows presented poster abstracts at a special evening session. Participants noted that this program has become exceptional in recent years as outstanding young scientists contend for acceptance and participation.
The EIGHTEENTH ASPEN CANCER CONFERENCE (2003): Mechanisms of Toxicity, Cancer Prevention and Cancer Therapy was held July 20-23, 2003. International experts presented and discussed timely topics including chromatin remodeling, molecular diagnostics, cancer prevention, therapy, telomeres, stem cells, functional genomics, imaging/tumor dormancy, and paradoxes in safety assessment. The Keynote Address, “Nuclear Cloning and the Reversibility of Cancer”, was presented by Rudolf Jaenisch, M.D., from the Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. Dr. Jaenisch was introduced to conference participants by J. Michael Bishop, M.D., a regular Aspen Cancer Conference attendee from the University of California, San Francisco. Preceding the Keynote Address, participants were entertained with a special piano recital by award winning pianist, Karen Allred. The poster abstract session featured fifteen scientific fellows and was considered by conference investigators as outstanding.
The SEVENTEENTH ASPEN CANCER CONFERENCE (2002): Mechanisms of Toxicity, Cancer Prevention and Cancer Therapy was held July 14-16, 2002. Subjects included chromatin remodeling, genetic instability, protein degradation, rational cancer therapy, mitochondrial structure and function in cell death, emerging technology in pharmacological research and development, animal models, cellular stress and signal transduction, stem cells, and safety assessment in the development of chemotherapeutics. A Special Lecture on the subject of "p53, Apoptosis and Aging" was given by Scott Lowe, Ph.D., from Cold Spring Harbor Laboratory, and a panel discussion on approaches to regulation was convened with J. Michael Bishop, M.D., Jane Henney, M.D., Tona Gilmer, Ph.D. and Scott Lowe, Ph.D. The poster abstract session featured fifteen young investigators and was considered by conference investigators as outstanding.
Expanded sessions at the SIXTEENTH ASPEN CANCER CONFERENCE (2001) included presentations and discussions on the following topics: chromosomal dynamics, cellular immortality, biomarkers of cancer, emerging technology, nuclear import and export, rational cancer therapy, experimental models of carcinogenesis, and cellular stress. The Keynote Address was presented by Stanley Korsmeyer, M.D., Harvard Medical School, on the subject of "The Mitochondrial Gateway to Apoptosis". Ten Aspen Cancer Conference Young Investigators presented their research studies at a special poster session and actively participated in the Conference. Another notable event was a special lecture by Dr. Peter Cerutti titled, "From Science to Art: The Way I See It". Dr. Cerutti, a prominent research scientist for many years, chose to change careers five years ago and is now a successful artist.
The FIFTEENTH ASPEN CANCER CONFERENCE WORKSHOP: Mechanisms of Toxicity, Carcinogenesis, and Cancer Prevention was held July 16-18, 2000. The subjects addressed were: genomic instability, DNA repair and centrosome fidelity, molecular mechanisms of cellular immortality, cause and prevention of hormonal cancer, regulatory implications of biomarkers of exposure and effect, apoptosis, chemoprevention, microarray technology in toxicology and cancer therapy, PPAR’s, nuclear export and import, and rational cancer therapy: signalling pathways. Leading scientists from academia, industry, and government productively interacted in the discussion of central scientific advances and issues that cut across the diverse interests of the scientific, regulatory, and public health communities. The FOURTEENTH ASPEN CANCER CONFERENCE considered in depth the following topics: signalling pathways as targets for therapy and prevention; chronic tissue injury; predictive toxicology; genetic instability and cell cycle control; microbial oncogenesis; molecular pathways of development; animal models of cancer; and apoptosis. Tony Hunter, Ph.D., (The Salk Institute) presented the Keynote Address, “Cancer Research and Therapy in the New Millenium,” and was presented the Aspen Cancer Conference Award. Young Investigators, sponsored by the Aspen Cancer Conference, presented their research findings at a poster session and actively participated in the Conference.
At the THIRTEENTH ASPEN CANCER CONFERENCE WORKSHOP, worldwide experts discussed the latest advances in the following topics: angiogenesis; basic science to therapy; advances in molecular therapy; stromal-epithelial interactions; epigenetic factors in carcinogenesis; molecular developmental pathways; new advances in molecular diagnosis of cancer; molecular epidemiology; microbial oncogenesis; and apoptosis. The discussion of each topic covered the mechanistic and regulatory implications of the latest advances in toxicology and carcinogenesis. The Program Committee of the Aspen Cancer Conference selected eight of these topics for the expanded Conference in 1999.
Expanded sessions at the TWELFTH ASPEN CANCER CONFERENCE (1997) included several presentations and discussions on the following topics: DNA repair, cell death, translational research, status of molecular diagnosis, carcinogen assessment strategy, mechanistic paradigms in risk assessment, cancer therapy, and tumor progression. The Keynote Address was presented by Thea Tlsty, Ph.D., on the subject "Loss of Genomic Integrity in Preneoplastic Cells." Students participating in the overlapping M.D.-Ph.D. Conference at the Given Institute attended a number of the sessions and Aspen Cancer Conference Young Investigators presented posters on subjects related to the theme.
At the ELEVENTH ASPEN CANCER CONFERENCE WORKSHOP: Mechanisms of Toxicity and Carcinogenesis (1996), the subjects included cell death, mechanistic paradigms of risk assessment, signal transduction, status of molecular diagnosis, carcinogen assessment strategy, tumor progression, oxidants and antioxidants in carcinogenesis, therapy, significance of stem cells, non-genotoxic carcinogenesis, and endogenous carcinogens.
The topics of the NINTH ASPEN CANCER CONFERENCE WORKSHOP were the focus of presentations made at the 1995 ASPEN CANCER CONFERENCE: Mechanisms of Toxicity and Carcinogenesis, which was the TENTH ANNIVERSARY of the ASPEN CANCER CONFERENCE. As part of the TENTH ANNIVERSARY celebration, a joint meeting with the Aspen M.D.-Ph.D. Student Conference was held on July 16, 1995. Donald West King, M.D., Founder of the Given Institute of Pathobiology, was honored and a keynote address entitled "Cell Biology and Molecular Genetics of Multistage Tumor Development" was given by Douglas Hanahan, University of California at San Francisco. Poster sessions were presented by the M.D.-Ph.D. students and the ASPEN CANCER CONFERENCE Young Investigators. The CONFERENCE was very interactive, multi-disciplinary, and informative, which is the tradition of this timely CONFERENCE.
The NINTH ASPEN CANCER CONFERENCE WORKSHOP: Mechanisms of Toxicity and Carcinogenesis, held in July 1994, explored in depth the following: nuclear structure and function, DNA synthesis and repair, control of the cell cycle, mechanisms of cell death, induction and inhibition of terminal differentiation, molecular mechanisms of senescence and immortality, implications of rodent liver carcinogenesis research for comparative and human cancer risks, molecular epidemiology of human cancer risk, new strategies for toxicity and carcinogenesis testing, and innovative approaches to cancer therapy. The EIGHTH ASPEN CANCER CONFERENCE: Molecular Mechanisms of Toxicity in Relation to the Genetics of Animal and Human Neoplasia, held in July, 1993, explored the biology and control of the cell cycle, mitosis, and aging; genomic instability including alterations of tumor suppressor genes and DNA methylation and deamination; cellular and molecular progression of neoplasia of the skin and brain; proto-oncogenes in cell signalling; methods and results for interspecies comparisons in mutagenesis and carcinogenesis; new concepts in molecular epidemiology; new approaches to cancer risk assessment; and molecular mechanisms of accidental and programmed cell death. In addition to the invited speakers and participants, several students and young investigators took part and reviewed their work in these respective areas in the form of poster sessions, as was done at the ASPEN CANCER CONFERENCES in 1987, 1989, and 1991.
The SEVENTH ASPEN CANCER CONFERENCE WORKSHOP: Mechanisms of Toxicity and Carcinogenesis, held in July 1992, considered, in depth, the following topics: cellular stress and mitogenesis, cellular development and programmed death, genomic instability, oncogenes and tumor suppressor genes, inherited cancer predisposition, molecular epidemiology and cancer risk assessment, and anticarcinogenesis - dietary and growth factor influences.
THE SIXTH ASPEN CANCER CONFERENCE: Molecular Mechanisms of Genetic Deregulation in Toxicity and Carcinogenesis, held in July 1991, explored the mechanism of altered DNA replication. A number of models, including oxidant stress, were considered. It is evident that factors resulting from stimuli to cells must be explained in terms of their effects on cell division, cell differentiation, and cell death. Sessions included the following areas: mitosis and genomic instability, oncogenes and tumor suppression, positive and negative growth factors, oxyradicals, anticarcinogenesis, in vitro and in vivo-knockout models in biology and carcinogenesis, molecular epidemiology, and biotechnology.
In 1990 we organized the FIFTH ASPEN CANCER CONFERENCE WORKSHOP: Recent Advances in Genetic Deregulation, Toxicology, and Carcinogenesis to plan the 1991 CONFERENCE. It became apparent that much more information was needed on the basic aspects of cell injury as related to cell replication, terminal differentiation, and chromosome anomalies, including the fundamental aspects of DNA replication, repair, and differentiation. Although the process of cell division is complex and will continue to require study in special models, it also became apparent at this WORKSHOP that we need to look at human cells as well. Because biotechnology plays a pivotal role in biomedical research, we also considered the human genome project and new developments in microscopy, including digital imaging fluorescence microscopy (DIFM) and atomic force microscopy (AFM). The potential of these new technologies was considered in detail the next year. The FOURTH ASPEN CANCER CONFERENCE, Carcinogenesis: From Molecular Mechanisms to Molecular Epidemiology (1989) focused on signal transduction and molecular carcinogenesis, provided especially thought-provoking insights into current and future problems in these areas as they relate to human risk and to the future of biochemical and molecular epidemiology. A Workshop on Toxicity, Tumor Promotion, and Carcinogenesis (THE FIRST ASPEN CANCER CONFERENCE) was held in Aspen in July of 1985 under the auspices of Universities Associated for Research and Education in Pathology (UAREP). The success of this CONFERENCE stimulated the planning committee to organize a follow-up CONFERENCE for July of 1987. The 1987 ASPEN CANCER CONFERENCE: Mechanisms of Carcinogenesis and Emerging Concepts of Technology, received high praise for so effectively filling the gap between previously held conferences. The 1988 ASPEN CANCER CONFERENCE Workshop developed the theme of Molecular Mechanisms.
|
sign to expand. Some years also have corresponding abstracts available.
|